VC-backed Translate Bio goes public

Lexington, Massachusetts-based Translate Bio Inc, a messenger RNA therapeutics company, has raised about $121.6 million for its IPO after pricing its 9.35 million shares at $13 per share. The stock began trading June 28, 2018 on the NASDAQ under the ticker symbol “TBIO.” Citigroup, Leerink Partners and Evercore ISI are the lead underwriters. Translate Bio’s pre-IPO backers include M Ventures, SR One, Leerink Partners, Partners Innovation Fund and Rock Springs Capital, according to Crunchbase.

PRESS RELEASE

LEXINGTON, Mass.–(BUSINESS WIRE)–Translate Bio, Inc. (Nasdaq: TBIO) a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced the pricing of its initial public offering of 9,350,000 shares of its common stock at a price to the public of $13.00 per share, for total gross proceeds of approximately $121.6 million, before deducting underwriting discounts and commissions and expenses payable by Translate Bio. In addition, Translate Bio has granted the underwriters a 30-day option to purchase up to 1,402,500 additional shares of common stock at the public offering price, less underwriting discounts and commissions, to cover over-allotments, if any. All of the shares are being offered by Translate Bio. The shares are expected to begin trading on the Nasdaq Global Select Market on June 28, 2018 under the symbol “TBIO.” The offering is expected to close on July 2, 2018, subject to customary closing conditions.

Citigroup, Leerink Partners and Evercore ISI are acting as joint book-running managers for the offering.
A registration statement relating to the shares being sold in this offering was declared effective by the Securities and Exchange Commission on June 27, 2018. The offering is being made only by means of a prospectus. When available, a copy of the final prospectus may be obtained by contacting Citigroup Global Markets Inc. c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by telephone at 1-800-831-9146; Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at 1-800-808-7525, ext. 6132, or by email at syndicate@leerink.com; or Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 36th Floor, New York, New York 10055, by telephone at 888-474-0200, or by email at ecm.prospectus@evercore.com.

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Translate Bio
Translate Bio is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction.